Type Public company Founded 1995 | Products Pharmaceuticals CFO August J. Moretti | |
Traded as NASDAQ: DEPO
S&P 600 Component Industry Pharmaceutical Industry Revenue US$342.7 million (2015) Operating income Stock price DEPO (NASDAQ) US$ 15.50 -0.46 (-2.88%)6 Mar, 4:00 PM GMT-5 - Disclaimer Headquarters Newark, California, United States CEO James A. Schoeneck (18 Apr 2011–) SVPs Jeff Coon, Matthew M. Gosling, August J. Moretti, Thadd M. Vargas (Business Development) Subsidiaries Depo DR Sub LLC, Depo NF Sub, LLC, Depomed Bermuda Ltd | ||
Depomed, Inc. is an American specialty pharmaceutical company which mainly markets products for treatment in neurology, pain and diseases of the central nervous system. Depomed was founded in 1995 and is headquartered in Newark, California. The company is a publicly traded company on NASDAQ under the symbol "DEPO", with several products approved by the United States Food and Drug Administration (FDA).
Contents
- The next big thing in biotech depomed
- Products
- For Pain
- For diabetes and others
- Acquisition
- Lawsuits
- References
The next big thing in biotech depomed
Products
The company's products include Nucynta ER, Nucynta, Gralise, Cambia, Lazanda, Zipsor, and DM-1992, which mainly focus on pain, neuropathic pain, and central nervous system diseases.
For Pain
Nucynta ER, Nucynta IR
On January 15, 2015, Depomed announced the acquisition of the Nucynta franchise from Janssen Pharmaceutica for US$1,050,000,000 in cash. The transaction closed on April 2, 2015, and the products are scheduled to be relaunched in June 2015 after a major salesforce expansion.
Gralise
In January 2011, Gralise once-daily (gabapentin extended release) was approved by the US FDA for the treatment of postherpetic neuralgia. The drug has also received Orphan Drug designation from the FDA.
For diabetes and others
The company's diabetes treatment, Glumetza (metformin hydrochloride extended release tablet), was approved for the treatment of type II diabetes in adults, and is sold in the US by Valeant.
Acquisition
In June 2012, all rights to Zipsor Liquid Filled Capsules was acquired by Depomed from Xanodyne Pharmaceuticals, revenue generated by Zipsor was approximately US$19,000,000 as within the twelve months from Jun 2011 to May 2012.
Lawsuits
In March 2012, the company filed a patent infringement lawsuit against three companies that had filed Abbreviated New Drug Applications with the US FDA, claiming infringement of Depomed's six US patents listed for Gralise in the FDA's Orange Book.